» Articles » PMID: 26185082

From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms

Overview
Specialty Microbiology
Date 2015 Jul 18
PMID 26185082
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Fungal infections constitute a major threat to an escalating number of critically ill patients. Fungi are eukaryotic organisms and, as such, there is a limited armamentarium of antifungal drugs, which leads to high mortality rates. Moreover, fungal infections are often associated with the formation of biofilms, which contribute to virulence and further complicate treatment due to the high level of antifungal drug resistance displayed by sessile cells within these microbial communities. Thus, the treatment of fungal infections associated with a biofilm etiology represents a formidable and unmet clinical challenge. The increasing importance and awareness of fungal biofilms is reflected by the fact that this is now an area of very active research. Studies in the last decade have provided important insights into fungal biofilm biology, physiology, and pathology, as well as into the molecular basis of biofilm resistance. Here we discuss how this accumulated knowledge may inform the development of new antibiofilm strategies and therapeutics that are urgently needed.

Citing Articles

The riboflavin biosynthetic pathway as a novel target for antifungal drugs against species.

Nysten J, Peetermans A, Vaneynde D, Jacobs S, Demuyser L, Van Dijck P mBio. 2024; 15(11):e0250224.

PMID: 39404356 PMC: 11559065. DOI: 10.1128/mbio.02502-24.


Antifungal metabolites, their novel sources, and targets to combat drug resistance.

Choudhary M, Kumar V, Naik B, Verma A, Saris P, Kumar V Front Microbiol. 2022; 13:1061603.

PMID: 36532457 PMC: 9755354. DOI: 10.3389/fmicb.2022.1061603.


Identification of Distinct Characteristics of Antibiofilm Peptides and Prospection of Diverse Sources for Efficacious Sequences.

Bose B, Downey T, Ramasubramanian A, Anastasiu D Front Microbiol. 2022; 12:783284.

PMID: 35185814 PMC: 8856603. DOI: 10.3389/fmicb.2021.783284.


Mechanistic Understanding of Biofilm Formation and Approaches for Its Inhibition.

Atriwal T, Azeem K, Husain F, Hussain A, Khan M, Alajmi M Front Microbiol. 2021; 12:638609.

PMID: 33995297 PMC: 8121174. DOI: 10.3389/fmicb.2021.638609.


Approaches for Mitigating Microbial Biofilm-Related Drug Resistance: A Focus on Micro- and Nanotechnologies.

Rao H, Choo S, Rajeswari Mahalingam S, Adisuri D, Madhavan P, Md Akim A Molecules. 2021; 26(7).

PMID: 33810292 PMC: 8036581. DOI: 10.3390/molecules26071870.


References
1.
Srinivasan A, Leung K, Lopez-Ribot J, Ramasubramanian A . High-throughput nano-biofilm microarray for antifungal drug discovery. mBio. 2013; 4(4). PMC: 3697808. DOI: 10.1128/mBio.00331-13. View

2.
Raad I . Intravascular-catheter-related infections. Lancet. 1998; 351(9106):893-8. DOI: 10.1016/S0140-6736(97)10006-X. View

3.
Walraven C, Lee S . Antifungal lock therapy. Antimicrob Agents Chemother. 2012; 57(1):1-8. PMC: 3535896. DOI: 10.1128/AAC.masthead.57-1. View

4.
Martins M, Lazzell A, Lopez-Ribot J, Henriques M, Oliveira R . Effect of exogenous administration of Candida albicans autoregulatory alcohols in a murine model of hematogenously disseminated candidiasis. J Basic Microbiol. 2011; 52(4):487-91. DOI: 10.1002/jobm.201100158. View

5.
Pierce C, Srinivasan A, Uppuluri P, Ramasubramanian A, Lopez-Ribot J . Antifungal therapy with an emphasis on biofilms. Curr Opin Pharmacol. 2013; 13(5):726-30. PMC: 3795934. DOI: 10.1016/j.coph.2013.08.008. View